PMID- 36551623
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221225
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 24
DP  - 2022 Dec 13
TI  - Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial 
      Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma.
LID - 10.3390/cancers14246139 [doi]
LID - 6139
AB  - The present study clarified the prognosis of intermediate-stage hepatocellular 
      carcinoma (HCC) patients who received lenvatinib (LEN) followed by transcatheter 
      arterial chemoembolization (TACE) on demand. We retrospectively evaluated 88 
      intermediate-stage HCC patients who received LEN. The median age was 74 (range: 
      47-92) years old, 67 patients were male, and 82 were classified as Child-Pugh A. 
      LEN was administered until disease progression or discontinuation due to adverse 
      events (AEs). The mean duration of LEN treatment was 7.0 months. The response and 
      disease control rates were 51.1% and 89.8%, respectively. The median 
      progression-free survival and overall survival (OS) after the initiation of LEN 
      were 6.8 months and 29.9 months, respectively. The OS in patients for whom LEN 
      was re-administered after TACE (TACE-LEN) was better than that in patients who 
      received other therapies (e.g., only TACE, TACE-other therapy, or only other 
      therapy) even with propensity score matching (p = 0.008). A Cox proportional 
      hazard analysis showed that TACE-LEN was most strongly associated with the OS 
      (hazard ratio: 0.083, 95% confidence interval: 0.019-0.362, p = 0.001). LEN was 
      administered for approximately 11.1 months after TACE. In intermediate-stage HCC 
      patients who can tolerate LEN without discontinuation due to AEs, TACE-LEN may 
      prolong the prognosis.
FAU - Mawatari, Seiichi
AU  - Mawatari S
AUID- ORCID: 0000-0002-3847-1065
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Tamai, Tsutomu
AU  - Tamai T
AD  - Department of Gastroenterology and Hepatology, Kagoshima City Hospital, Kagoshima 
      8908760, Japan.
FAU - Kumagai, Kotaro
AU  - Kumagai K
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Saisyoji, Akiko
AU  - Saisyoji A
AD  - Department of Hepatology, Kagoshima Kouseiren Hospital, Kagoshima 8900062, Japan.
FAU - Muromachi, Kaori
AU  - Muromachi K
AD  - Department of Gastroenterology and Hepatology, Kagoshima City Hospital, Kagoshima 
      8908760, Japan.
FAU - Toyodome, Ai
AU  - Toyodome A
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Taniyama, Ohki
AU  - Taniyama O
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Sakae, Haruka
AU  - Sakae H
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Ijuin, Sho
AU  - Ijuin S
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Tabu, Kazuaki
AU  - Tabu K
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Oda, Kohei
AU  - Oda K
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Hiramine, Yasunari
AU  - Hiramine Y
AD  - Department of Hepatology, Kagoshima Kouseiren Hospital, Kagoshima 8900062, Japan.
FAU - Moriuchi, Akihiro
AU  - Moriuchi A
AD  - Department of Gastroenterology, National Hospital Organization Kagoshima Medical 
      Center, Kagoshima 8920853, Japan.
FAU - Sakurai, Kazuhiro
AU  - Sakurai K
AD  - Department of Gastroenterology, National Hospital Organization Kagoshima Medical 
      Center, Kagoshima 8920853, Japan.
FAU - Kanmura, Shuji
AU  - Kanmura S
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
FAU - Ido, Akio
AU  - Ido A
AD  - Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, 
      Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 
      8908544, Japan.
LA  - eng
PT  - Journal Article
DEP - 20221213
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9776720
OTO - NOTNLM
OT  - TACE
OT  - hepatocellular carcinoma (HCC)
OT  - intermediate stage
OT  - lenvatinib
OT  - on demand
COIS- A.I. received the scholarship grants from EISAI Co., Ltd. The company had no role 
      in study design, data collection and analysis, decision to publish, or 
      preparation of the manuscript. The other authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/13
CRDT- 2022/12/23 01:11
PHST- 2022/11/10 00:00 [received]
PHST- 2022/12/05 00:00 [revised]
PHST- 2022/12/09 00:00 [accepted]
PHST- 2022/12/23 01:11 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/13 00:00 [pmc-release]
AID - cancers14246139 [pii]
AID - cancers-14-06139 [pii]
AID - 10.3390/cancers14246139 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Dec 13;14(24):6139. doi: 10.3390/cancers14246139.